Diuretics for Management of Bronchopulmonary Dysplasia Associated Pulmonary Hypertension in Preterm Infants-A Systematic Review.
- 1Division of Neonatology, Department of Pediatrics University of British Columbia and British Columbia Women's Hospital Vancouver British Columbia Canada.
- 2Division of Neonatology, Department of Pediatrics University of Ottawa and Children's Hospital of Eastern Ontario Ottawa Ontario Canada.
- 3Department of Health Research Methods, Evidence and Impact McMaster University Hamilton Ontario Canada.
Abstract
Bronchopulmonary dysplasia associated pulmonary hypertension (BPD-PH) in preterm infants results from impaired pulmonary vascular development and contributes significantly to morbidity and mortality. Diuretics are commonly used to reduce pulmonary vascular congestion and improve oxygenation, but their efficacy and safety remain unclear. This systematic review aimed to evaluate the efficacy and safety of diuretic use in preterm infants with BPD-PH. Primary outcomes were mortality and need for home respiratory support; secondary outcomes were echocardiographic and clinical parameters, and adverse effects such as hyponatremia, nephrocalcinosis. We searched MEDLINE, Embase, Cochrane Central, and ClinicalTrials.gov from inception to October 2025. We included randomized controlled trials (RCTs) and non-randomized studies of interventions (NRSI) evaluating diuretics in preterm infants (< 32 weeks' gestation) with BPD-PH diagnosed by echocardiography at 36 weeks postmenstrual age. Two reviewers independently performed data extraction and risk-of-bias assessment (ROBINS-I). Outcomes were synthesized narratively, and a meta-analysis was performed where sufficient data were available. Of 492 studies identified, 2 NRSI (n = 49) met inclusion criteria, both were at serious risk of bias. No RCTs exist on diuretics for BPD-PH in preterm infants. Mortality, respiratory, discharge outcomes and adverse effects were reported inconsistently. Meta-analysis of limited data demonstrated small improvements in echocardiographic markers, but the certainty of evidence was very low due to heterogeneity between the two included studies. To conclude, evidence supporting the use of diuretics in BPD-PH in preterm infants remains limited and of low certainty. High quality studies are needed to better define their safety and efficacy.
Related
- Intensification of blood pressure lowering therapeutics based on diuretics versus usual management for uncontrolled hypertension in patients with moderate to severe chronic kidney disease (THINK): protocol for an open label, two-parallel group, cluster randomised controlled, superiority, phase 3 trial
- FOXF1 and alveolar-vascular dysregulation in bronchopulmonary dysplasia-associated pulmonary hypertension.
- Prevalence and factors associated with pulmonary hypertension in patients undergoing maintenance hemodialysis: a systematic review and meta-analysis
- Early Tracheal and Salivary miRNAs in Extremely Preterm Infants Predict Bronchopulmonary Dysplasia-Related Pulmonary Hypertension.
- Endohepatology in the Management of Portal Hypertension in Metabolic Dysfunction‐Associated Steatotic Liver Disease
BibTeX
@article{kanagaraj2026diuretics,
title = {{Diuretics for Management of Bronchopulmonary Dysplasia Associated Pulmonary Hypertension in Preterm Infants-A Systematic Review.}},
author = {Uthaya Kumaran Kanagaraj and Ayman Saker and Carlos Cuello-Garcia and Michael Castaldo and Sandesh Shivananda},
journal = {Pulmonary circulation},
year = {2026},
month = oct,
doi = {10.1002/pul2.70440},
url = {https://europepmc.org/article/MED/42953377},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Diuretics for Management of Bronchopulmonary Dysplasia Associated Pulmonary Hypertension in Preterm Infants-A Systematic Review.
AU - Uthaya Kumaran Kanagaraj
AU - Ayman Saker
AU - Carlos Cuello-Garcia
AU - Michael Castaldo
AU - Sandesh Shivananda
PY - 2026
DA - 2026/10/28
JO - Pulmonary circulation
DO - 10.1002/pul2.70440
UR - https://europepmc.org/article/MED/42953377
AB - Bronchopulmonary dysplasia associated pulmonary hypertension (BPD-PH) in preterm infants results from impaired pulmonary vascular development and contributes significantly to morbidity and mortality. Diuretics are commonly used to reduce pulmonary vascular congestion and improve oxygenation, but their efficacy and safety remain unclear. This systematic review aimed to evaluate the efficacy and safety of diuretic use in preterm infants with BPD-PH. Primary outcomes were mortality and need for home respiratory support; secondary outcomes were echocardiographic and clinical parameters, and adverse effects such as hyponatremia, nephrocalcinosis. We searched MEDLINE, Embase, Cochrane Central, and ClinicalTrials.gov from inception to October 2025. We included randomized controlled trials (RCTs) and non-randomized studies of interventions (NRSI) evaluating diuretics in preterm infants (< 32 weeks' gestation) with BPD-PH diagnosed by echocardiography at 36 weeks postmenstrual age. Two reviewers independently performed data extraction and risk-of-bias assessment (ROBINS-I). Outcomes were synthesized narratively, and a meta-analysis was performed where sufficient data were available. Of 492 studies identified, 2 NRSI (n = 49) met inclusion criteria, both were at serious risk of bias. No RCTs exist on diuretics for BPD-PH in preterm infants. Mortality, respiratory, discharge outcomes and adverse effects were reported inconsistently. Meta-analysis of limited data demonstrated small improvements in echocardiographic markers, but the certainty of evidence was very low due to heterogeneity between the two included studies. To conclude, evidence supporting the use of diuretics in BPD-PH in preterm infants remains limited and of low certainty. High quality studies are needed to better define their safety and efficacy.
SN - 2045-8932
SN - 2045-8940
ER -